11/02/2019 17:14:26

C-Bridge Capital Forms AffaMed Therapeutics to Accelerate Commercialization of Biologics in China

SHANGHAI, China, Feb. 11, 2019 (GLOBE NEWSWIRE) -- AffaMed Therapeutics, a new biopharmaceutical company founded and funded by C-Bridge Capital, a healthcare private equity firm focused on the development and late-stage investment opportunities, announced today that it is partnering with Samsung Bioepis to accelerate the commercialization of multiple next-generation biosimilars in China. Pharmaceutical industry veteran, Dr. Nathan Pang, will lead the Company as CEO.

The licensed products include SB3 referencing trastuzumab (Herceptin®), which received approval from the U.S. Food & Drug Administration (FDA) and European Medicines Agency for sale in the European Union, SB11 referencing ranibizumab (Lucentis®), which is currently undergoing Phase 3 trials in the U.S and SB12 referencing eculizumab (Soliris®).

“Dr. Pang’s deep industry knowledge and extensive leadership skills will be invaluable as the company develops and expands its portfolio of products,” said Dr. Michael Keyoung, M.D., Ph.D., Chair of the Board of Directors at AffaMed and Managing Director at C-Bridge Capital. “His previous leadership roles coupled with his expertise of the biopharmaceutical industry make him well suited to lead AffaMed.”

Dr. Pang has more than 20 years of experience as a physician and a healthcare executive. Prior to joining AffaMed Therapeutics, he was the General Manager of Sanofi Pasteur China, where he expanded the company’s pipeline by securing licensing agreements with Janssen China and Merck (MSD) China. Before that, he was the CEO of Sandoz China, the Generics Division of Novartis Group, during which he started up and grew the business to an organization with commercialised portfolio and profitable revenue. Previously, he was the Asia Pacific Regional Head for the Novartis Oncology Business Unit overseeing 14 countries in Asia including China. Dr. Pang holds a Bachelor of Medicine; Bachelor of Surgery (M.B.B.S) from the National University of Singapore and Bachelor of Law from the University of London, as well as a dual EMBA from France’s INSEAD and China’s Tsinghua University.

“We are thrilled to partner with Samsung Bioepis, a proven leader in the global biosimilar industry, to develop these next-generation biologic candidates for patients in China,” Dr. Pang said. “Our team’s clinical, regulatory and commercial experience with innovative biologics makes AffaMed uniquely suited to advance the development and registration of these products in China.”

About AffaMed Therapeutics

AffaMed Therapeutics is a biopharmaceutical company focused on identifying and licensing late-stage candidates for commercialization in emerging Asia Pacific markets and globally. AffaMed was founded and funded by C-Bridge Capital in 2019.

About C-Bridge Capital

C-Bridge Capital is a healthcare dedicated private equity firm, focused on growth and late-stage investment opportunities across the healthcare industry. C-Bridge Capital is committed to supporting the commercialization of cutting-edge technologies and companies that fulfil unmet medical needs, thus continuously improving the standard and quality of care for patients.

Contacts:

Media in US and Europe:

James Heins

Senior Vice President

Westwicke PR, an ICR Company

Tel. +1 203-682-8251

James.Heins@icrinc.com

Media in Asia:

Edmond Lococo

Senior Vice Present

ICR Asia

+86(10) 6583-7510

Edmond.lococo@icrinc.com

logo-c.jpg

Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
12 Feb
VELO
Hvis agendaen er at komme i en god position for en samlet overtagelse - er de vel godt på vej. I hve..
31
13 Feb
VELO
Her er nogle spørgsmål som jeg ønsker besvaret. Håber i andre vil bidrage med flere spørgsmål som JP..
24
12 Feb
PNDORA
Uden at skulle fremsætte nogen konspirationsteorier så finder jeg det personligt ganske interasant a..
23
12 Feb
GOMX
I får det seriøst til at lyde somom GomX er på vej ned og snakker dommedag 😂! Hallo bois!! Det førs..
20
15 Feb
VELO
Jeg kan se på FB-gruppen at er der en diskussion omkring præparatet fra Hansa Medical det evt. ramme..
19
11 Feb
VWS
MHI Vestas named as Preferred Supplier for 476 MW Baltic Eagle project in Germany http://www.mhivest..
18
15 Feb
VELO
Jeg har solgt mine Veloxis-aktier, for der er nogle mekanismer i stigningerne i både Chemometec og i..
17
12 Feb
PNDORA
Fuldstændig uenig.Noget af Pandoras fald er absolut berettiget, ingen tvivl om det!   MEN.Pandora ha..
16
11 Feb
DSV
Der er nogen i denne her tråd, der burde skamme sig, og derefter lære at holde deres ubegavede ringe..
15
13 Feb
FING-B
Sådan skal de nye FPS kort fra Fingerprint Cards aktiveres. Smukt og ligetil https://m.youtube.com/..
14

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

Related news
22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Avon Products, Inc. (AVP) and Encourages AVP Investors to Contact the Firm
2
Bragar Eagel & Squire, P.C. is Investigating Certain Officers and Directors of Venator Materials PLC (VNTR) and Encourages VNTR Investors to Contact the Firm
3
Bragar Eagel & Squire, P.C. is Investigating Mattel, Inc. (MAT) on Behalf of Stockholders and Encourages MAT Investors to Contact the Firm
4
Bragar Eagel & Squire, P.C. Announces That Class Action Lawsuits Have Been Filed Against Molson Coors Brewing Company (TAP) and Encourages TAP Investors to Contact the Firm
5
200 First Responders to participate in Texas A&M Task Force 1 full-scale drill at Disaster City®

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
16 February 2019 16:30:59
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20190215.1 - EUROWEB1 - 2019-02-16 17:30:59 - 2019-02-16 16:30:59 - 1000 - Website: OKAY